Bloemena, E.

patient pylori eradication therapy study group biopsy gastriti liver nsaid e ffect placebo group 6- tg disease placebo pylori eradication 6- tg therapy 6- tg dosage eradication group corpus flammatory helicobacter regenerative hyperplasia dosage thioguanine level ibd patients helicobacter pylori 6- thioguanine antrum helicobacter pylori infection number specimen treatment atrophy flammatory bowel disease result liver biopsy center thiopurine hyperplasia bowel nsaid users ulcer 6- tgn level 6- tgn levels gastroenterology gastroprotective vu university regenerative nding eradication therapy flammation month metaplasia 6- thioguanine therapy 6- tg use laboratory helicobacter pylori eradication nsaid therapy infection table hepatotoxicity fference 20 mg nsaid treatment 6- mp 6- mercaptopurine netherland gastroenterol randomized presence range trial di fferences gastroprotective drugs histology ef ficacy anti-in university